Metformin-induced AMP-activated protein kinase activation regulates phenylephrine-mediated contraction of rat aorta

Biochemical and Biophysical Research Communications

Volumn 421, Issue 3, 2012, Pages 599-604

  Sung, Jin Young ^a   Choi, Hyoung Chul ^a  

^a Yeungnam University   (South Korea)

Author keywords

AMPK; Contraction; LKB1; Metformin; MLCK; P MLC; VSMC

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; MYOSIN LIGHT CHAIN KINASE; PHENYLEPHRINE;

ANIMAL EXPERIMENT; AORTA; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ENZYME ACTIVATION; MALE; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE RELAXATION; VASCULAR RING; VASCULAR SMOOTH MUSCLE; VASOMOTOR REFLEX;

ACTINS; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AORTA; BLOOD PRESSURE; ENZYME ACTIVATION; HYPERTENSION; METFORMIN; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; MYOSIN LIGHT CHAINS; PHENYLEPHRINE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS; VASOCONSTRICTION;

RATTUS;

EID: 84860674142     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.04.052     Document Type: Article

References (31)

1. Hardie D.G., Scott J.W., Pan D.A., Hudson E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 2003, 546:113-120.
2. Ford R.J., Rush J.W. Endothelium-dependent vasorelaxation to the AMPK activator AICAR is enhanced in aorta from hypertensive rats and is NO and EDCF dependent. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:64-75.
3. Hardin C.D., Wiseman R.W., Kushmerick M.J. Tension responses of sheep aorta to simultaneous decreases in phosphocreatine, inorganic phosphate and ATP. J. Physiol. 1992, 458:139-150.
4. Krisanda J.M., Paul R.J. Phosphagen and metabolite content during contraction in porcine carotid artery. Am. J. Physiol. 1983, 244:385-390.
5. Morrow V.A., Foufelle F., Connell J.M., Petrie J.R., Gould G.W., Salt I.P. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J. Biol. Chem. 2003, 278:31629-31639.
6. Chen Z., Peng I.C., Sun W., Su M.I., Hsu P.H., Fu Y., Zhu Y., DeFea K., Pan S., Tsai M.D., Shyy J.Y. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ. Res. 2009, 104:496-505.
7. Bassel-Duby R., Olson E.N. Signaling pathways in skeletal muscle remodeling. Annu. Rev. Biochem. 2006, 75:19-37.
8. Mu J., Brozinick J.T., Valladares O., Bucan M., Birnbaum M.J. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol. Cell 2001, 7:1085-1094.
9. 2+/calmodulin-dependent kinases in skeletal muscle plasticity. J. Appl. Physiol. 2005, 99:414-423.
10. Woods A., Johnstone S.R., Dickerson K., Leiper F.C., Fryer L.G., Neumann D., Schlattner U., Wallimann T., Carlson M., Carling D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 2003, 13:2004-2008.
11. 2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2005, 2:21-33.
12. 2+ sensitization of the contractile apparatus in vascular smooth muscle. J. Pharmacol. Sci. 2007, 104:109-115.
13. Thatcher S.E., Fultz M.E., Tanaka H., Hagiwara H., Zhang H.L., Zhang Y., Hayakawa K., Yoshiyama S., Nakamura A., Wang H.H., Katayama T., Watanabe M., Lin Y., Wright G.L., Kohama K. Myosin light chain kinase/actin interaction in phorbol dibutyrate-stimulated smooth muscle cells. J. Pharmacol. Sci. 2011, 116:116-127.
14. Lee J.H., Koh H., Kim M., Kim Y., Lee S.Y., Karess R.E., Lee S.H., Shong M., Kim J.M., Kim J., Chung J. Energy-dependent regulation of cell structure by AMP-activated protein kinase. Nature 2007, 447:1017-1020.
15. Adelstein R.S., Eisenberg E. Regulation and kinetics of the actin-myosin-ATP interaction. Annu. Rev. Biochem. 1980, 49:921-956.
16. Davis M.J., Hill M.A. Signaling mechanisms underlying the vascular myogenic response. Physiol. Rev. 1999, 79:387-423.
17. Hawley S.A., Gadalla A.E., Olsen G.S., Hardie D.G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002, 51:2420-2425.
18. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol. Rev. 2003, 83:1325-1358.
19. Horman S., Morel N., Vertommen D., Hussain N., Neumann D., Beauloye C., El Najjar N., Forcet C., Viollet B., Walsh M.P., Hue L., Rider M.H. AMP-activated protein kinase phosphorylates and desensitizes smooth muscle myosin light chain kinase. J. Biol. Chem. 2008, 283:18505-18512.
20. Alessi D.R., Sakamoto K., Bayascas J.R. LKB1-dependent signaling pathways. Annu. Rev. Biochem. 2006, 75:137-163.
21. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Mäkelä T.P., Alessi D.R., Hardie D.G. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2003, 2:28.
22. Allen B.G., Walsh M.P. The biochemical basis of the regulation of smooth-muscle contraction. Trends Biochem. Sci. 1994, 19:362-368.
23. Hartshorne D.J. Biochemical basis for contraction of vascular smooth muscle. Chest 1980, 78:140-149.
24. Dong Y., Zhang M., Wang S., Liang B., Zhao Z., Liu C., Wu M., Choi H.C., Lyons T.J., Zou M.H. Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo. Diabetes 2010, 59:1386-1396.
25. Dong Y., Zhang M., Liang B., Xie Z., Zhao Z., Asfa S., Choi H.C., Zou M.H. Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation 2010, 121:792-803.
26. Buhl E.S., Jessen N., Pold R., Ledet T., Flyvbjerg A., Pedersen S.B., Pedersen O., Schmitz O., Lund S. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 2002, 51:2199-2206.
27. Rivera L., Morón R., Zarzuelo A., Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol. 2009, 77:1053-1063.
28. Michael S.K., Surks H.K., Wang Y., Zhu Y., Blanton R., Jamnongjit M., Aronovitz M., Baur W., Ohtani K., Wilkerson M.K., Bonev A.D., Nelson M.T., Karas R.H., Mendelsohn M.E. High blood pressure arising from a defect in vascular function. Proc. Natl. Acad. Sci. USA 2008, 105:6702-6707.
29. Wong A.K., Howie J., Petrie J.R., Lang C.C. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin. Sci. 2009, 116:607-620.
30. Zou M.H., Kirkpatrick S.S., Davis B.J., Nelson J.S., Wiles W.G., Schlattner U., Neumann D., Brownlee M., Freeman M.B., Goldman M.H. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J. Biol. Chem. 2004, 279:43940-43951.
31. Davis B.J., Xie Z., Viollet B., Zou M.H. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006, 55:496-505.